Improving target assessment in biomedical research: the GOT-IT recommendations.
Improving target assessment in biomedical research: the GOT-IT recommendations.
复制标题
DOI：
10.1038/s41573-020-0087-3
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Parnham MJ
中科院分区：
文献类型：
--
作者：
Emmerich CH;Gamboa LM;Hofmann MCJ;Bonin-Andresen M;Arbach O;Schendel P;Gerlach B;Hempel K;Bespalov A;Dirnagl U;Parnham MJ
学术研究在确定新药靶标方面发挥着关键作用，包括了解靶标生物学以及靶标与疾病状态之间的联系。然而，为了开发新药，研究必须从纯粹的学术探索发展到在临床试验中识别和测试候选药物的努力，这通常由生物制药行业进行。通过及时关注靶标评估方面，如靶标相关的安全性问题、可药性和可测性，以及靶标调节实现与现有疗法的区别的可能性，可以促进这一过渡。在这里，我们介绍GOT-IT工作组的建议，这些建议旨在支持学术科学家和转化研究的资助者确定目标评估活动的优先顺序，并确定实现科学目标的关键路径，以及与许可、与行业合作或启动临床开发计划相关的目标。基于不同目标评估领域的指导性问题集，GOT-IT框架旨在激发学术科学家对使翻译研究更稳健和更有效的因素的认识，并促进学术界和产业界的合作。学术研究在确定新药靶点方面发挥着关键作用，但为了开发新药，这项研究必须在临床试验中测试候选药物，这通常是由行业进行的。这一视角提供了一个框架，以支持学术科学家和资助者优先考虑目标评估活动，并确定实现科学目标的关键路径，以及与许可、与行业合作或启动临床试验相关的目标。
Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. This transition can be facilitated by a timely focus on target assessment aspects such as target-related safety issues, druggability and assayability, as well as the potential for target modulation to achieve differentiation from established therapies. Here, we present recommendations from the GOT-IT working group, which have been designed to support academic scientists and funders of translational research in identifying and prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical development programmes. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is intended to stimulate academic scientists’ awareness of factors that make translational research more robust and efficient, and to facilitate academia–industry collaboration. Academic research has a key role in identifying new drug targets, but to lead to new drugs this research must progress to testing drug candidates in clinical trials, which are typically conducted by industry. This Perspective presents a framework to support academic scientists and funders in prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical trials.
影响因子：
9.8
作者：
Lee WH
通讯作者：
Lee WH